SCHEMBL266150

SCHEMBL266150

C[CH]CC(N)c1cccc(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.51
ADRA1A P35348 2/20 0.51
MIF P14174 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2B P41595 1/20 0.51
HIF1A Q16665 4/20 0.45
ADRB2 P07550 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADRB3 P13945 1/20 0.45
TSHR P16473 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
NFKB1 P19838 1/20 0.45
DRD1 P21728 1/20 0.45
HTR7 P34969 1/20 0.45
ADRA1B P35368 1/20 0.45
DRD3 P35462 1/20 0.45
RAB9A P51151 1/20 0.45
SLC6A3 Q01959 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL633773 0.79 ADRB1 (0.56) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL15157484 0.79 ADRB1 (0.56) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL265739 0.79 PNMT (0.44) OPRM1OPRK1
Hydrochloric Acid SCHEMBL4931729 0.78 ADRB1 (0.55) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL268751 0.77 ESR1 (0.43) ADRA1AHIF1AHTR1ATSHRNFKB1
SCHEMBL10455404 0.77 ADRB1 (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL266309 0.77 SCN4A (0.45)
SCHEMBL18774941 0.76 ADRB1 (0.58) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL12056795 0.76 ADRB1 (0.53) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL267088 0.76 AOC3 (0.49) ALDH1A1CYP3A4ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431378-B2 Aminotransferase, gene encoding the same, and methods of using them KANEKA CORPORATION (JP) 2013-04-30 US disclosed
US-20120164724-A1 NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM KANEKA CORPORATION (JP) 2012-06-28 US disclosed
US-8133705-B2 Aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2012-03-13 US disclosed
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2010-11-11 US disclosed
EP-1889907-B1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME KANEKA CORP (JP) 2009-09-02 EP disclosed
EP-1889907-A1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2008-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them BCAT1, AGXT, ALDH7A1 ADRB1 4315/4885ADRA1A 4304/4885MIF 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.